Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b/4 Open-label Study of mRNA COVID-19 Variant-containing Vaccines
2026-000101-14Phase 3
- Sponsor
- Moderna Inc
- Start
- May 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of Imelasomeran, mRNA-1273.712, mRNA-1273.251 and mRNA-1273.261 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Moderna Inc. Primary endpoints: Geometric Mean Value of Neutralizing Antibody Against COVID-19 Variants and Safety of updated mRNA COVID-19 variant-containing vaccines.
02
Drugs
ImelasomeranmRNA-1273.712mRNA-1273.251mRNA-1273.261
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2026-000101-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-000101-14.